Plain-English translation of NCT05296681 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a microbiotic product called can help people with advanced colon cancer who are receiving chemotherapy. The medication is a specially formulated drink designed to promote healthy gut bacteria. Researchers believe that a healthier gut microbiome may help the body better tolerate chemotherapy and reduce severe side effects like diarrhea.
Chemotherapy drugs like irinotecan can damage the healthy bacteria in your gut, causing severe diarrhea that sometimes forces doctors to reduce or delay treatment doses. This trial is testing whether supporting your gut bacteria with this medication before and during chemotherapy might prevent that damage and help you stay on your full treatment schedule.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive the microbiotic drink or standard chemotherapy alone. Those receiving the drink will start taking it four times daily (before meals and after dinner) five days before your chemotherapy begins, and continue for 56 days. You will also receive irinotecan-based chemotherapy according to standard care. The study will monitor your diarrhea levels, how well the chemotherapy works, and use blood and stool tests to track changes in your gut bacteria and gut health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States